Workflow
生物健康
icon
Search documents
鱼鳞、鱼皮成“宝贝”!人才“沃土”叠加发展“活水”给足民企从0到1底气
Yang Shi Wang· 2025-06-20 06:04
央视网消息:鱼鳞、鱼皮,这些鱼身上的边角料能做什么用?在海南,有家企业敢为人先,创新性将这些边角料"变废为宝",产品获得50 多个国家和地区市场的欢迎,成为海南海洋经济新赛道上的重要一员。 海南华研胶原科技股份有限公司,一家专注于海洋生物健康食品研发的国家级高新技术企业。这批刚到货的鱼鳞正在被清洗,在这里,它们将 通过物料运输管道开启"变身"之路。 企业负责人赵子方介绍,他们正在以鱼鳞和鱼皮为原料,生产他们的"拳头产品"——胶原蛋白环二肽。海南华研从事生物健康食品生产已经有 20年了,以前他们生产的相关保健品产品附加值低、同质化严重。近几年,他们在市场调研过程中发现,老年人对胶原蛋白环二肽的需求非常 大,而这个市场还是个空白。 赵子方介绍,他们找到了国外文献里面对环二肽的一些报道,环二肽在国外会作为一种化学合成药物来预防老年痴呆。他们想在银发经济,中 老年功能性食品上做一些布局。 通过查阅国外的资料他们发现,国外学者10年前就尝试过利用胶原蛋白肽来制取环二肽,但是获得率仅为千分之几,因为难度太大,最终没有 做出产品,不了了之。现在,一家中国的民营企业想干同样的事,能在全世界率先实现突破吗? 当时,海南华研不仅 ...
青岛琅琊台集团41.79%国有股权无偿划转
Sou Hu Cai Jing· 2025-06-13 15:16
Core Viewpoint - The transfer of state-owned equity in the Qingdao Langyatai Group to the Qingdao West Coast Health Industry Development Group represents a significant move in the reform of state-owned enterprises and the promotion of industrial clustering in the West Coast New Area [2][3] Group 1: Equity Transfer Details - On June 11, Qingdao Haikong Group announced the transfer of its 41.79% stake in Langyatai Group to the Health Industry Group without compensation [2][5] - Following the transfer, the Health Industry Group will become the new controlling shareholder of Langyatai Group, while the employee shareholding ratio remains unchanged [5] Group 2: Company Background - Langyatai Group, originally established as Qingdao First Brewery in 1958, has transformed from a single liquor producer to a diversified industrial group, becoming one of the top 100 enterprises in China's liquor industry [4] - As of the end of 2024, Langyatai Group has total assets of 2.559 billion yuan and net assets of 769 million yuan, with an operating income of 541 million yuan and a net profit of 18.5854 million yuan [5] Group 3: Health Industry Group Overview - The Health Industry Group, established in 2018, is a new force within the Qingdao state-owned asset system, with a registered capital of 500 million yuan [7] - By the end of 2024, its asset scale reached 9.387 billion yuan, which is 3.7 times that of Langyatai Group, but it only achieved a net profit of 6 million yuan and has total liabilities of 5.946 billion yuan [8] Group 4: Strategic Implications - The equity transfer is not merely an asset maneuver but a strategic move to enhance resource synergy between the Health Industry Group and Langyatai Group, particularly in the biomedicine sector [10][13] - Langyatai Group's expertise in marine biotechnology and the Health Industry Group's medical resources could create a closed-loop ecosystem for research, production, and application in the health industry [14]